drugset / Trial / NCT03281577

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

NCT03281577

Phase 2 Completed 36 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.

Timeline

Start
2018-01-02
Primary completion
2019-06-07
Completion
2019-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject felcisetrag Small molecule 0.1 mg Intravenous
Subject felcisetrag Small molecule 0.3 mg Intravenous
Subject felcisetrag Small molecule 1 mg Intravenous